Home Magazines Editors-in-Chief FAQs Contact Us

Drug treatment of chronic hepatitis b in Brazil: a review


Gastroenterology & Hepatology: Open Access
Geanne da Silva Lobato,1 Ademilton Alves Farias,1 Araceli Maria Barbosa Belo,1 Loiane Barbosa Brito,1 Alessandra Pereira da Silva,2 José Raul Rocha de Araújo Júnior1

Abstract

Hepatitis B is a liver infection caused by the Hepatitis B virus, which can be chronic, exposing the population to a high risk of death from cirrhosis and liver cancer. The treatment of HBV in Brazil is currently carried out according to the protocol of therapeutic guidelines, which recommends the use of drugs Tenofovir, Entecavir, Adefovir, Lamivudine, Interferon-alpha and Peg-interferon. The aim of this study is to demonstrate aspects of drug therapy for chronic hepatitis B in Brazil. This study was carried out through a bibliographic review, in the databases PubMed, “Scientific Electronic Library Online” (SciELO) and Google Academics, in the period from 2011 to 2021. A total of thirty-four scientific articles were analyzed. In general, the drugs recommended for the treatment of chronic hepatitis B in Brazil are nucleoside inhibitors of reverse transcriptase and immunomodulators. These drugs have several adverse reactions, such as headache, nausea, vomiting, abdominal pain, diarrhea, dizziness. The choice of treatment may be influenced by the HBV got more effective, with less adverse reactions and that increase the patient's adherence to the treatment, enabling a better quality of life.

Keywords

hepatitis B chronic, Hepatitis B virus, therapy, antiviral, HBV, hepatitis B viruses, SVR, sustained virological response, SVR, sustained virological response, LMV, lamivudine, ADV, adefovir, ETV, entecavir, TDF, tenofovir

Testimonials